The Chinese Stroke Association scientific statement: intravenous thrombolysis in acute ischaemic stroke

The most effective medical treatment for acute ischaemic stroke (AIS) is to offer intravenous thrombolysis during the ultra-early period of time after the onset. Even based on the Consensus of Chinese Experts on Intravenous Thrombolysis for AIS in 2012 and 2014 Chinese Guidelines on the Diagnosis an...

Descripción completa

Detalles Bibliográficos
Autores principales: Dong, Qiang, Dong, Yi, Liu, Liping, Xu, Anding, Zhang, Yusheng, Zheng, Huaguang, Wang, Yongjun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Stroke & Vascular Neurology 2017
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5628383/
https://www.ncbi.nlm.nih.gov/pubmed/28989804
http://dx.doi.org/10.1136/svn-2017-000074
Descripción
Sumario:The most effective medical treatment for acute ischaemic stroke (AIS) is to offer intravenous thrombolysis during the ultra-early period of time after the onset. Even based on the Consensus of Chinese Experts on Intravenous Thrombolysis for AIS in 2012 and 2014 Chinese Guidelines on the Diagnosis and Treatment of AIS, the rate of thrombolysis for AIS in China remained around 2.4%, and the rate of intravenous tissue plasminogen activator usage was only about 1.6% in real world. The indication of thrombolysis for AIS has been expanded, and contraindications have been reduced with recently published studies. In order to facilitate the standardisation of treating AIS, improve the rate of thrombolysis and benefit patients who had a stroke, Chinese Stroke Association has organised and developed this scientific statement.

Ejemplares similares